LATAM MedTech Insights

This episode of LATAM MedTech Insights dives into a sudden and critical regulatory update from Colombia's INVIMA. Last week's clarification on Unique Device Identification (UDI) for Class IIa devices has created an immediate compliance challenge for manufacturers, requiring a new level of data management and specific submission protocols that have caught many off guard. We break down what the new guidance entails, the technical hurdles it presents, and the broader implications for MedTech companies operating in, or planning to enter, the Colombian market. We explore why this move is more than a simple labeling change and represents a significant step-up in local enforcement of global standards. A leading US-based orthopedic company, which packages multiple devices into single surgical kits, is now facing potential import blockades. Their global UDI strategy did not account for INVIMA's new demand for individual Device Identifier linking for every single Class IIa component within a kit. This case study reveals the hidden complexities and the urgent need to overhaul their data management systems to meet Colombia’s unique requirements. --- **Key Takeaways:** 1. What are the exact technical data points INVIMA now requires for UDI-DI registration linking? 2. Is your current local representative in Colombia equipped to handle these new digital submission requirements? 3. How does this UDI update affect devices that are already on the market versus new registrations? 4. What are the specific Spanish-language documentation requirements that could trip up your submission? 5. If your product is part of a kit, what is the new compliance burden you urgently need to address? 6. Could this sudden enforcement approach from INVIMA be a sign of future regulatory trends in Peru or Chile? 7. What is the real financial risk of having your products detained at Colombian customs due to non-compliance? --- At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Whether it's managing UDI compliance in Colombia or developing a regulatory strategy for over 30 markets worldwide, we act as your local representative to ensure you maintain market presence. Don't let regulatory surprises disrupt your business. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the impactful new regulations quietly introduced in Chile. Exempt Decree No. 25 has significantly expanded the oversight of the national health authority, the ISP, reshaping the compliance landscape for many medical device manufacturers who previously had an easier path to market. We dive into the specifics of what this decree means for your product portfolio, the new registration and surveillance demands you need to be aware of, and the broader implications for the Latin American MedTech market. This is a critical update for anyone operating in or planning to enter Chile. A specific case involves a US-based diagnostics company that saw its projected launch timeline in Chile triple overnight. Their devices, once subject to a simple notification process, are now under the full scope of Decree 25, requiring a comprehensive regulatory submission they were completely unprepared for, jeopardizing their entire regional expansion plan. Key Takeaways: - What is Chile's Exempt Decree No. 25 and which devices does it suddenly affect? - How does this change impact time-to-market and costs for MedTech companies? - Is your current product portfolio compliant with the ISP's newly expanded oversight? - Why is this seemingly small decree a major signal for the entire LATAM region's regulatory future? - What are the three immediate steps you must take to de-risk your Chilean market strategy? - How can you leverage your existing technical documentation for the new requirements? - Could these stricter rules actually create a competitive advantage for well-prepared companies? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

Last week, Brazil's regulatory landscape for MedTech was redefined. ANVISA, the national health agency, unexpectedly rolled out a stringent new framework mandating advanced cybersecurity and data privacy compliance for all AI-driven medical devices. This sudden move disrupts market-entry plans and forces an immediate re-evaluation of regulatory strategies for companies targeting Latin America's largest market. This episode dives deep into the practical consequences of this new regulation. We break down the specific documentation now required, from threat modeling to LGPD compliance, and analyze why simply leveraging your existing FDA or CE Mark approval is no longer a viable path to market access in Brazil. **Key Questions Answered in This Episode:** * What are the specific cybersecurity protocols ANVISA now demands for AI-enabled devices? * How does this new regulation intersect with Brazil's data protection law, the LGPD? * Why is my existing international documentation suddenly insufficient for a Brazilian submission? * What is the single biggest risk for MedTech startups trying to navigate this new rule? * How can this regulatory hurdle be turned into a competitive advantage? * What immediate steps should your company take to de-risk your market entry plan for Brazil? * Are there any "hidden" requirements in the new resolution that could delay your launch? Don't let regulatory hurdles block your access to the vibrant LATAM market. Pure Global combines local expertise with AI-powered data tools to streamline your path to compliance and success. From market access strategy to local representation, we offer end-to-end solutions for MedTech and IVD innovators. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.

This week, we dissect a game-changing regulatory update from Brazil's ANVISA that directly impacts AI-powered medical devices. Brazil has introduced a mandatory "Algorithm Change Protocol" for all Software as a Medical Device (SaMD), creating a new, complex layer of requirements that surpasses current FDA and EU standards. This change is already causing submission delays for unprepared companies. We explore what this new protocol entails, why ANVISA is taking this assertive step, and what it means for your LATAM market access strategy. This episode provides essential insights for any MedTech manufacturer looking to launch AI-driven technologies in Latin America's largest market. Don't let this unexpected hurdle derail your expansion plans. **Key Questions Answered:** * What is the new "Algorithm Change Protocol" that ANVISA now requires for all AI-based SaMD? * Why is your existing FDA or CE-marked technical file suddenly insufficient for Brazil? * How does this update specifically impact SaMD for diagnostic imaging versus therapeutic applications? * What are the immediate costs and timeline delays if this protocol is missing from your submission? * How can you proactively build this protocol into your Quality Management System? * Is this a sign of a broader regulatory trend across other LATAM countries? * What are the top three mistakes companies make when trying to meet these new AI documentation rules? At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts, powered by advanced AI tools, provides end-to-end solutions to get your MedTech and IVD products to market efficiently. From developing a robust regulatory strategy and compiling technical dossiers to acting as your official in-country representative, we streamline your access to over 30 global markets, including Brazil. Don't let regulatory surprises slow you down. Contact us at [email protected] or visit https://pureglobal.com to learn more.

This week, we dissect the immediate fallout from Brazil's surprise new regulation, ANVISA RDC 925/2026. This sudden rule change for AI-powered medical software has blindsided many international MedTech companies, creating significant new hurdles for entry into Latin America's largest market. We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity protocols is forcing companies to scrap their existing market access strategies. This isn't just another piece of red tape. it's a fundamental shift that could delay product launches by more than a year and add millions to the cost. **Featured Case:** Imagine a promising MedTech scale-up, armed with FDA clearance and a robust set of clinical data from the US. Their plan for a quick Brazilian launch is abruptly halted by the new ANVISA rule. Their "gold-standard" clinical data is now deemed insufficient, and their global cybersecurity framework is non-compliant. They now face a critical decision: invest in a costly, time-consuming local trial and data-system overhaul, or abandon the market entirely. **Key Questions Answered in This Episode:** * How does ANVISA's new rule redefine "sufficient" clinical data for AI medical devices? * What specific LGPD cybersecurity measures are now mandatory for your SaMD to be approved in Brazil? * Can you leverage your existing FDA or CE marking to fast-track any part of the new process? * What is the most common blind spot for foreign companies when interpreting these new requirements? * How can you turn this regulatory hurdle into a strategic advantage in the LATAM market? * Does this new resolution signal a wider protectionist trend across other Latin American markets? Navigating the complexities of global MedTech regulations is our expertise. Pure Global offers end-to-end regulatory consulting solutions, combining local expertise with advanced AI and data tools to streamline your market access. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit us at https://pureglobal.com/ for a strategic consultation.

Brazil's health regulatory agency, ANVISA, has just released a groundbreaking new framework for Software as a Medical Device (SaMD), creating significant new challenges for global MedTech innovators. This update introduces stricter requirements for clinical data and cybersecurity, tailored specifically to the Brazilian context. This policy shift is forcing international companies to rethink their market entry strategies, as regulatory dossiers approved in other major markets may no longer be adequate. Imagine your AI-powered diagnostic tool, which has already received CE marking, being rejected by ANVISA because its validation data doesn't reflect Brazil's diverse population and its data servers aren't localized. This is the new reality, where overlooking local nuances can lead to costly delays and missed opportunities. Key Takeaways: - What specific cybersecurity protocols are now mandatory under ANVISA's new SaMD resolution? - How can you gather clinical data that meets the new requirements for representing the Brazilian population? - Can your existing EU MDR or FDA documentation be leveraged, or do you need to start from scratch for Brazil? - What are the common pitfalls when appointing a Brazil Registration Holder for a complex SaMD product? - What are the new labeling requirements for AI-powered devices regarding transparency and performance? - How does Brazil's General Data Protection Law, the LGPD, intersect with these new ANVISA regulations? - Is it more strategic to partner with a local entity or establish a subsidiary to meet the new compliance demands? Struggling to keep up with these changes? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Contact us for a strategic consultation at [email protected] or visit us at https://pureglobal.com.

This week, we dive into a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just rolled out a comprehensive and demanding new framework for Software as a Medical Device (SaMD), directly impacting AI-driven diagnostics and digital health platforms. We break down what these changes mean for market access. We explore the challenges through the case of a medical AI company. Their market entry plan for Brazil was solid, but the new regulations suddenly made their existing documentation obsolete. Now they face the critical risk of misclassifying their device, which could lead to costly delays and outright rejection by ANVISA. This episode is a must-listen for innovators looking to enter or expand in Brazil. Key Takeaways: - How does ANVISA's new risk classification for software differ from the FDA and EU MDR frameworks? - What are the most common documentation gaps that will lead to rejection under the new SaMD rules? - Are your current cybersecurity protocols sufficient to meet Brazil's stringent new requirements? - How can you leverage your existing clinical data for a successful Brazilian submission? - What specific post-market surveillance activities does ANVISA now expect from SaMD manufacturers? - Could this new regulation actually accelerate market entry for companies that are properly prepared? At Pure Global, we specialize in turning regulatory complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end regulatory consulting to ensure your MedTech and IVD products achieve seamless market access. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can streamline your entry into over 30 global markets.

In this episode, we dissect the groundbreaking new resolution from Brazil's ANVISA that creates a fast-track approval pathway for AI-powered Software as a Medical Device (SaMD). This regulatory shift is set to drastically reduce time-to-market, from years to mere months, for cutting-edge digital health technologies in Latin America's largest healthcare market. We explore the specific requirements, the immense opportunities for global MedTech innovators, and the new compliance challenges related to cybersecurity and post-market surveillance. This change signals a new era for MedTech in Brazil, creating a powerful incentive for companies to invest and expand their footprint in the region. Case in Point: Imagine your innovative AI diagnostic tool, already approved in the US, is blocked from the 215 million-person Brazilian market by a slow, outdated regulatory system. You've spent years in development, and now face a three-year waiting period filled with uncertainty and mounting costs, while patients are deprived of your technology. This was the reality for many, but last week's ANVISA announcement changes everything, presenting a golden opportunity, but also a complex new set of rules to master. Key Takeaways: * What specific changes did ANVISA just implement for AI-powered medical devices? * How does this new fast-track process actually work, and who is eligible to apply? * Are there hidden risks or compliance traps in the new Brazilian cybersecurity requirements? * Which international companies are best positioned to capitalize on this regulatory shift first? * Will Mexico's COFEPRIS or Argentina's ANMAT now follow Brazil's lead? * How can you leverage existing FDA or CE Mark dossiers for the new Brazilian pathway? * What are the new, stricter post-market surveillance demands for SaMD in Brazil? Pure Global offers end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate these complexities. We combine local expertise with advanced AI and data tools to streamline your global market access, acting as your local representative and ensuring your technical dossiers meet ANVISA's new requirements. To accelerate your entry into the Brazilian market and beyond, contact us at [email protected] or visit https://pureglobal.com/.

Brazil's regulatory body, ANVISA, has just released its strategic agenda for 2026-2027, signaling the most significant shift in the country's MedTech landscape in years. This isn't just a routine update; it's a complete overhaul of key regulations that will redefine market access for international medical device companies. For prepared firms, this opens the door to streamlined entry into Latin America's largest market. For the unprepared, it could mean being locked out entirely. We dive deep into the specifics, moving beyond the headlines to analyze the real-world impact of these changes. We uncover the hidden opportunities and critical threats buried in the new agenda, focusing on the upcoming revolution in Software as a Medical Device (SaMD) rules and the game-changing proposal to make MDSAP certification mandatory. **Key Questions Answered in This Episode:** * What does ANVISA's new agenda mean for my Software as a Medical Device (SaMD) product? * Is mandatory MDSAP participation coming to Brazil, and how should my company prepare? * How will changes to Good Manufacturing Practice certificate validity affect my registration renewals? * Are the new regulations creating a faster path to market or a higher wall for entry? * How can I align my global regulatory strategy with Brazil's push for international harmonization? * What are the three most critical action items my team should focus on in the next quarter? * Could these changes make Brazil a more predictable market than other LATAM countries? Struggling to decode ANVISA's new agenda? Pure Global offers end-to-end regulatory consulting to turn these challenges into opportunities. With local experts in Brazil and advanced AI tools, we streamline your market access strategy, manage technical dossier submissions, and act as your official in-country representative. Don't let regulatory complexity block your entry into Latin America's powerhouse market. Contact us for a strategic assessment at [email protected] or visit https://pureglobal.com/.

In this episode, we dissect the breaking news from Brazil where ANVISA has just released an urgent and aggressive new cybersecurity resolution, RDC 999/2026. This sudden move imposes tight deadlines on both new and existing connected medical devices, forcing manufacturers to quickly adapt or risk losing market access in Latin America's largest market. We explore the immediate impact on international MedTech companies, many of whom are now scrambling to meet the complex new requirements. This resolution is more than a simple compliance update; it's a signal of a major strategic shift in how Brazil, and potentially the rest of LATAM, will regulate the future of digital health technology. **What You'll Learn:** * What are the immediate, critical deadlines in ANVISA's new cybersecurity resolution? * Why is simply translating your existing EU or FDA technical file no longer sufficient for Brazil? * How does Brazil's data privacy law (LGPD) create unique challenges for device manufacturers? * What is the single biggest risk facing legacy medical devices already on the Brazilian market? * Could this regulatory shockwave in Brazil trigger a domino effect across Colombia and Mexico? * What are the three essential steps your company must take now to avoid market access denial? * How can you turn this regulatory hurdle into a competitive advantage in the LATAM region? Struggling to keep up with the fast-changing regulatory landscape in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, ensuring you're always ahead of the curve. Don't let regulatory surprises derail your strategy. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure and accelerate your entry into over 30 global markets.

This week on LATAM MedTech Insights, we are tackling the crisis unfolding with Mexico's new digital submission platform for medical devices. COFEPRIS aimed for modernization, but the reality for many manufacturers is a cascade of technical failures and confusing new data regulations that are derailing market entry plans. We dissect what is really happening on the ground in Mexico City. We explore the critical gap between regulatory ambition and practical execution, revealing the unwritten rules that are now essential for approval. This episode is a must-listen for anyone targeting the Mexican market. Imagine a European scale-up, ready to launch its innovative AI-powered diagnostic tool, has its submission rejected. The reason is a new, vaguely-worded data localization rule their standard global dossier did not account for. They now face a six-month delay and thousands in unforeseen costs, all because of a change that was never formally announced. What you will learn in this episode: 1. What are the top three technical glitches currently plaguing the new COFEPRIS platform? 2. Why is the new 'data localization' requirement catching even experienced regulatory professionals by surprise? 3. How can you determine if your cloud-based medical device complies with these unwritten rules? 4. What specific steps should your company take right now if you have a submission pending in Mexico? 5. Are local Mexican companies facing the same level of scrutiny as foreign applicants? 6. How can a local representative in Mexico City provide a critical advantage in overcoming these digital hurdles? 7. What does this situation signal about the future of MedTech regulation across Latin America? Navigating unpredictable regulatory shifts in Latin America is a major challenge. Pure Global specializes in turning these complexities into clear market access strategies. With our deep local expertise in Mexico and advanced AI-driven regulatory intelligence, we help MedTech and IVD companies avoid costly delays. From acting as your official local representative to compiling and managing flawless technical dossiers, we ensure your path to market is smooth and efficient. Do not let regulatory surprises derail your growth. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This week, we dissect the seismic news from Brazil. ANVISA just launched an accelerated approval pathway for AI-powered medical devices, creating a potential gold rush for MedTech innovators. This episode explores the immense opportunity for rapid market entry and the critical, hidden compliance challenges that come with it. We uncover the stringent new post-market surveillance and data reporting requirements that could trap unprepared manufacturers. Imagine securing a landmark approval for your diagnostic software in record time, only to face the risk of market withdrawal due to unforeseen data validation demands. This is the new high-stakes reality of the Brazilian MedTech market. Key Questions Answered: - What specific AI-powered medical devices are eligible for ANVISA's new fast-track registration? - How do the new post-market surveillance rules fundamentally change compliance in Brazil? - Why is a 'living' Clinical Evaluation Report now essential for maintaining your market access? - What are the hidden operational costs tied to these new continuous monitoring demands? - Could Mexico and Colombia be the next LATAM countries to follow Brazil's lead? - How can you leverage this accelerated pathway without falling into the compliance trap? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop efficient regulatory strategies, and manage the entire submission and compliance lifecycle, ensuring you can seize opportunities like this without the pitfalls. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

Brazil's health regulator, ANVISA, has just shaken up the digital health landscape. A new draft resolution brings critical clarifications for AI-powered medical software, creating a clearer but much stricter pathway to Latin America's largest market. This move could accelerate innovation for some, while creating major new hurdles for others. This episode unpacks the critical details of this regulatory shift. We explore the dilemma facing manufacturers of AI-driven diagnostics: the new rules provide a clearer roadmap for approval but demand an unprecedented level of control and documentation over adaptive algorithms and patient data, potentially stalling the very innovation they seek to foster. Key Takeaways From This Episode: - What are the specific new requirements for managing changes in AI/ML medical software in Brazil? - How does this new resolution interact with Brazil's General Data Protection Law (LGPD)? - Is your current Quality Management System prepared for these new post-market surveillance demands? - What kind of validation data will ANVISA now expect for adaptive algorithms? - How can you turn this regulatory tightening from a barrier into a competitive advantage? - Could Brazil's new AI software framework become the new standard for other LATAM markets? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

This week, we dive into a game-changing development out of Costa Rica. Long known as a premier manufacturing hub for MedTech, the country just launched the "Medical Device Innovation Pathway" (MDIP), a new accelerated registration process exclusively for locally manufactured devices. This move could redefine market entry strategies across Latin America, offering unprecedented speed but with significant new hurdles. We unpack what the MDIP truly entails, moving beyond the headlines to analyze the specific, challenging requirements hidden within this new regulation. This episode is essential for any MedTech leader who manufactures in, or is considering, Costa Rica as a strategic base for their LATAM operations. Case Study: Imagine you've invested millions in a state-of-the-art manufacturing facility in Costa Rica. The new MDIP promises a rapid launch into the LATAM market, but it comes with surprise local audits and stringent data-sharing clauses that your global compliance framework is not prepared for. Is this accelerated pathway a golden opportunity or a regulatory trap? What you will learn: - What are the specific terms of Costa Rica's new Medical Device Innovation Pathway? - Why is this new regulation a strategic "gambit" for the country's economy? - What are the top three hidden compliance traps in the new fast-track process? - How do the MDIP's quality system requirements differ from ISO 13485? - Could this "local-first" regulatory model be adopted by other LATAM countries? - How will this impact decisions for siting new manufacturing facilities in the region? - What are the critical questions to ask your regulatory team about this development today? At Pure Global, we specialize in turning complex regulatory challenges into clear market access strategies. Our team of local experts in Latin America provides on-the-ground support for everything from initial regulatory strategy and technical dossier submission to quality assurance and post-market surveillance. We help you navigate intricate local requirements like Costa Rica's MDIP, ensuring your path to market is both fast and compliant. Don't let regulatory surprises derail your launch. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect the latest critical guidance from Brazil's ANVISA on RDC 751, a regulation that aligns the country's medical device framework with the EU's MDR. This is more than a policy update. it's a strategic shift that redefines the requirements for market access in Latin America's powerhouse. We explore the immediate impact on technical dossiers, post-market surveillance, and the newly empowered role of the Brazil Registration Holder. This episode is for any MedTech manufacturer eyeing the Brazilian market. We break down the hidden complexities and strategic opportunities this presents. Imagine a global scale-up, already EU MDR approved, that believed its entry into Brazil would be seamless. They are now facing unexpected delays and costly rework because their technical file missed nuanced local requirements hidden within the new guidance. Their entire product launch is at risk. Key questions from this episode include: - Is your current technical file truly ready for ANVISA's new dossier structure? - How does the new risk classification system impact your device registration timeline? - What are the unwritten rules for post-market surveillance that ANVISA now expects? - Could your existing EU MDR strategy create unforeseen compliance gaps in Brazil? - Are you prepared for the expanded liability now placed on your Brazil Registration Holder? - What specific labeling and instruction-for-use changes are required immediately? - How can you leverage local representation to accelerate the new review process? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking new regulatory framework released by Brazil's ANVISA for AI-powered medical devices. Announced just last week, this move positions Brazil as a leader in digital health regulation in Latin America, but it also creates significant new hurdles for innovators looking to enter the market. We explore the specific requirements of the new resolution, including the critical and non-negotiable need for clinical data from the local Brazilian population. This change has immediate implications for international companies, potentially delaying market entry and adding significant costs. Understanding the nuances of this regulation is now the key to unlocking the Brazilian MedTech market. A real-world pain point: Imagine your company has developed a revolutionary AI diagnostic tool, validated with world-class data from the US and Europe. You're ready to launch in the massive Brazilian market, but ANVISA's new rule means your existing data is suddenly insufficient. You now face an unexpected 18-month delay and the seven-figure cost of running a new local clinical trial. This is the exact, urgent challenge companies are grappling with right now. Key Takeaways This Episode: 1. What are the specific risk classifications for AI software under ANVISA's new resolution? 2. Why is local Brazilian population data now a mandatory requirement for regulatory approval? 3. What is the compliance deadline for AI-powered devices that are already on the market? 4. How does this regulatory shift impact the investment landscape for digital health startups in Brazil? 5. Are other major LATAM markets like Mexico and Colombia expected to follow Brazil's lead? 6. What are the essential new components you must include in your technical dossier for a successful submission? 7. How can you strategically leverage this regulatory change as a competitive advantage instead of seeing it as a roadblock? Navigating complex regulatory shifts like this is what we do best. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don't let regulatory hurdles block your innovation. Contact Pure Global for a strategic consultation at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect a game-changing update from Brazil's regulatory agency, ANVISA. The validity for medical device registrations has been doubled from five to ten years. This sounds like great news, but it comes with a significant new hurdle: a mandatory mid-cycle compliance review that could catch unprepared companies off guard. We break down what this shift means for your long-term strategy in Latin America's biggest market. We explore the opportunities for reduced administrative burden and the hidden risks associated with the new, more stringent post-market surveillance requirements that underpin this extended registration period. Imagine your Class III device registration in Brazil is suddenly suspended five years into its new ten-year term. Your sales are frozen. This is the risk for manufacturers who misunderstand the new mid-cycle review. We discuss how to avoid this scenario by implementing a proactive compliance strategy from day one. Key Takeaways: - What specific documentation is required for ANVISA's new mid-cycle review? - How does the 10-year registration impact the role and responsibilities of a local Brazilian Registration Holder? - What are the biggest mistakes foreign manufacturers can make when adapting to this new regulation? - How should your Quality Management System be updated to handle continuous surveillance versus periodic renewal? - Does this change signal a wider trend towards longer registration cycles in other LATAM markets? - What are the specific post-market surveillance data points ANVISA will now scrutinize more closely? - How can you leverage this regulatory change to gain a competitive advantage in Brazil? At Pure Global, we provide the local expertise and strategic guidance to navigate these complex regulatory shifts. We offer end-to-end solutions, from initial market access strategy and technical dossier submission to managing your post-market surveillance and acting as your official in-country representative. To secure your market presence in Brazil and beyond, contact us at [email protected] or visit https://pureglobal.com/.

Last week, Brazil's ANVISA sent shockwaves through the MedTech industry by announcing a hard deadline for transitioning all medical device registrations to the new RDC 751 framework. In this episode, we break down what this sudden enforcement means for foreign manufacturers, moving beyond the headlines to reveal the hidden complexities and strategic risks. We explore why existing international dossiers, like those for CE marking, may not be enough and what specific gaps ANVISA is targeting, putting your market access in jeopardy. We examine the case of a European orthopedic implant company whose Brazilian sales were abruptly halted. Discover the critical flaw in their post-market surveillance plan that satisfied EU regulators but failed ANVISA's new, stricter review, forcing them into a costly and time-consuming remediation process. Key Takeaways for This Episode: 1. What is the number one mistake companies make when adapting their technical file for RDC 751? 2. Are your existing risk management and clinical evaluation reports truly compliant with Brazil's new requirements? 3. How can you avoid the common pitfalls that lead to registration suspension during this transition? 4. What specific labeling changes does ANVISA now require that could impact your supply chain? 5. Does your Brazil Registration Holder (BRH) have the technical expertise to defend your new dossier? 6. How will this surprise deadline impact your product launch timeline in Brazil for the next year? Don't let regulatory hurdles in Latin America derail your growth. Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing a robust regulatory strategy for Brazil to acting as your official in-country representative, we ensure your products meet ANVISA's demanding standards. Contact us to secure your market presence at [email protected] or visit https://pureglobal.com/ to learn more.

Mexico's regulatory authority, COFEPRIS, has just launched its mandatory all-digital submission platform, DigiPRIS. While this move promises to streamline market access, the initial rollout has created significant and unexpected challenges for medical device manufacturers, leading to submission errors, delays, and uncertainty. This episode of LATAM MedTech Insights unpacks the chaotic first week of the new system. We share a real-world case study of a cardiovascular device company whose complete digital submission vanished from the COFEPRIS portal without a trace after being successfully uploaded. This costly setback highlights the critical need for navigating the platform's undocumented requirements and technical instability. Key Takeaways in this episode: - What are the unwritten rules and hidden formatting requirements of the new DigiPRIS platform? - How can you verify your digital submission is secure and correctly processed by COFEPRIS? - What is the new timeline for approvals, and how does the digital system impact it? - Which device classes are most affected by the platform's initial instability? - What is the most effective way to communicate with COFEPRIS about a digital submission error? - How should you adapt your regulatory strategy to mitigate the risks of this digital transition? - Are there new cybersecurity concerns for your technical dossier on the DigiPRIS platform? At Pure Global, we specialize in navigating these complex regulatory shifts. Our local experts in Mexico combined with our advanced AI tools provide the real-time support needed to overcome digital barriers and ensure your product gets to market efficiently. Don't let digital chaos derail your launch. Contact Pure Global at [email protected] or visit https://pureglobal.com/.

In this episode, we dive into a critical regulatory update from Brazil that is sending shockwaves through the digital health community. Last week, ANVISA unexpectedly released a new instruction specifically targeting AI and Software as a Medical Device (SaMD), creating immediate hurdles for foreign manufacturers. We break down the three core changes involving clinical data, cybersecurity, and algorithm updates. This shift presents a major challenge for companies relying on international data and standard privacy protocols for their market entry. **Case In Point:** A German AI diagnostics firm, fully prepared for its Brazilian launch with a complete EU-validated data package, now faces a mandatory, year-long delay. They must initiate a new, costly local clinical study and re-engineer their data systems to comply with Brazil's specific privacy laws, jeopardizing their entire LATAM expansion strategy. **In this episode, you will learn:** * What are the specific new clinical data requirements for AI devices in Brazil? * How does Brazil's LGPD law now directly impact SaMD cybersecurity protocols? * Why might your existing FDA or CE mark for an AI device be insufficient for ANVISA? * What is the new, burdensome process for submitting simple algorithm updates? * Is it now impossible to enter the Brazilian market without local clinical trials? * Which types of SaMD are most affected by this surprise regulation? * What are the immediate steps you should take if you are planning a launch in Brazil? At Pure Global, we offer end-to-end regulatory consulting to help MedTech innovators navigate complex markets like Brazil. We combine local expertise with advanced AI tools to streamline global market access, from regulatory strategy and dossier submission to acting as your official in-country representative. To turn regulatory hurdles into market opportunities, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a sudden and pivotal regulatory shift in Brazil. ANVISA has just launched a new fast-track approval pathway for medium-risk medical devices, a move that could dramatically accelerate market entry. But this opportunity comes with a complex new requirement that is already tripping up unprepared manufacturers. In this episode, we break down exactly what ANVISA's new resolution entails. We explore the case of a German MedTech firm whose attempt to leverage this new fast-track process was immediately halted by a documentation mistake, highlighting a critical new pain point for foreign companies. This is a must-listen for any regulatory professional eyeing the Brazilian market. Key Questions from This Episode: - Does your existing FDA or CE clearance automatically qualify you for ANVISA's new fast-track process? - What is the single most common error companies are making in the new 'Comparative Regulatory Analysis' report? - How can you leverage your existing technical file to meet the stringent new local requirements in Brazil? - Why might your standard global registration strategy fail under this new Brazilian rule? - What specific expertise is now essential for a successful and speedy submission to ANVISA? - Is it possible to get your device approved in Brazil in under six months, and what's the secret? Navigating global markets requires more than just a great product; it demands flawless regulatory execution. At Pure Global, we provide end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We combine local expertise with advanced AI tools to streamline market access, manage technical dossiers, and ensure your submission is right the first time. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect the critical new amendment to Brazil's RDC 657 software regulations, a move by ANVISA that specifically targets AI and machine learning devices. The update introduces complex new requirements for clinical validation, post-market changes, and cybersecurity, significantly raising the bar for market entry. We explore what these changes mean for MedTech manufacturers, why Brazil is becoming one of the most demanding markets for digital health, and how companies can adapt their strategies to succeed. **Case Study:** Imagine your AI-powered diagnostic software, already successful in Europe and the US, is ready for its Brazilian launch. Suddenly, ANVISA's new amendment invalidates your entire clinical data package and demands a brand-new, localized study. How do you manage this unexpected, multi-million dollar roadblock without abandoning Latin America's largest market? **Key Takeaways:** - Does my AI software now need a separate validation dossier specifically for the Brazilian population? - What is a "Pre-approved Change Plan" and how do I submit one to ANVISA for my adaptive algorithm? - Are my current cybersecurity measures compliant with the newly mandated international standards? - How can I leverage my existing clinical data to meet the new local requirements without starting from scratch? - What are the new post-market surveillance duties for AI software that learns continuously? - Will this amendment affect the registration timeline for my non-AI software products as well? Navigating complex regulatory shifts like these is what we do best. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in over 30 markets, including Brazil. We use advanced AI and data tools to streamline your path to market access. Don't let regulatory hurdles block your innovation. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect breaking news from Brazil. ANVISA, the national health regulatory agency, has just launched a new fast-track pilot program for AI-powered medical software. This move could slash market entry timelines in half, but it comes with a host of new, complex requirements that could trap unprepared companies. We explore the specific opportunities this creates for MedTech innovators in the diagnostic space and the hidden challenges in clinical data and cybersecurity compliance that lie beneath the surface. This is a must-listen for any company looking to capitalize on Brazil's push to become a digital health powerhouse. Case Study Spotlight: A Brazilian startup created a revolutionary AI to detect a common cause of blindness. They were facing a two-year regulatory battle, risking their competitive edge. Now, a new door has opened, but it demands a completely different key. How can they pivot their regulatory strategy to meet aggressive new data validation standards without getting lost in the paperwork? Key Questions Answered: - What are the exact eligibility criteria for ANVISA's new SaMD fast-track program? - How does this new pathway impact foreign companies trying to enter the Brazilian market? - What are the new cybersecurity and data privacy demands hidden within this regulation? - Is this accelerated process a genuine opportunity or a new regulatory bottleneck? - How can you leverage existing international approvals, like FDA or CE, for this new process? - What are the most common mistakes companies make when submitting AI device dossiers in Brazil? At Pure Global, we specialize in demystifying these complex regulatory shifts. We offer end-to-end solutions, from market strategy and technical dossier preparation using advanced AI tools to serving as your official local representative in Brazil. Ready to accelerate your market access? Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's ANVISA just launched a new fast-track approval process for AI medical software, a huge opportunity for MedTech innovators. However, this golden ticket comes with a major catch: a strict data localization law that could derail market entry plans for unprepared international companies. This episode of LATAM MedTech Insights unpacks the new resolution and explores the critical strategic decisions that foreign device manufacturers now face. We delve into the dual nature of this regulation. It is both a massive opportunity to accelerate entry into a booming market and a significant operational hurdle that demands a sophisticated, localized strategy. **Case In Point:** A leading European AI diagnostics firm saw its Brazil market entry timeline cut by 75%, a massive win. The catch? Their entire cloud-based system is suddenly non-compliant under the new data sovereignty rules, forcing a painful and expensive choice: build local infrastructure from scratch or miss the window of opportunity entirely. **Key Takeaways From This Episode:** - What are the exact technical requirements of ANVISA's new resolution for AI software? - How can you leverage the new fast-track approval without falling into the data localization trap? - Is it more cost-effective to partner locally or build your own data infrastructure in Brazil? - What are the hidden cybersecurity compliance costs associated with this new rule? - How does this Brazilian policy signal a larger regulatory trend across Latin America? - What are the three critical questions your legal and IT teams should be asking right now? - Can your existing technical dossier be adapted for this new, faster submission process? - What are the IP protection risks when partnering with local data providers? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. We provide end-to-end solutions, from developing a compliant regulatory strategy and managing technical submissions with our AI-powered tools, to acting as your official local representative in Brazil. We help you navigate complex requirements like data localization so you can access new markets faster and with confidence. Contact us to learn how we can streamline your global expansion at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the seismic shift in Brazil's regulatory landscape. Last week, ANVISA issued an unexpected technical note on clinical evaluation requirements under RDC 751, fundamentally altering the path to market for many international device manufacturers. We explore the end of the 'easy' equivalence route based on CE or FDA clearance and what this means for your technical dossier, budget, and timeline. This isn't just a minor update; it's a strategic challenge that redefines market entry into Latin America's largest economy. Imagine you're a US-based orthopedic company, weeks away from submitting your dossier to ANVISA, only to find your entire clinical strategy, built on equivalence to your CE-marked device, is now invalid. We discuss the real-world scramble this has caused. In This Episode, We Uncover: 1. What specific clause in the new ANVISA note created this regulatory hurdle? 2. Why is relying on your existing CE mark or FDA 510(k) for equivalence in Brazil now a critical risk? 3. What are the three immediate strategic options for manufacturers affected by this change? 4. How does this shift impact the timeline and cost for new device registrations in Brazil? 5. Is it still possible to use the equivalence pathway, and if so, what is the new gold standard for a predicate device? 6. What does this move signal about ANVISA's long-term regulatory direction? 7. How can you proactively monitor for these kinds of 'surprise' updates from regulatory bodies? Navigating sudden regulatory shifts in LATAM requires more than just knowledge; it requires on-the-ground intelligence and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. Whether it's developing a new clinical strategy for Brazil or managing submissions across 30+ markets, we are your local representative. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.

Brazil's ANVISA just opened a fast-track approval process for AI medical devices, creating a huge opportunity for MedTech innovators. But this incredible speed comes with a hidden challenge: a new set of ultra-stringent cybersecurity regulations that are catching many companies off guard and threatening to derail their launch plans. Imagine a US-based scaleup, CardioVision AI, ready to enter Brazil with their FDA-cleared diagnostic software. They see ANVISA's new fast-track and are excited for a quick launch. But their team suddenly discovers the new rules demand a level of data encryption and mandatory local data hosting they hadn't prepared for. Their entire market entry timeline is now at risk, and the costs are mounting. This is the exact challenge many companies are now facing. Key Takeaways: - What are the exact requirements of ANVISA's new fast-track AI approval pathway? - How do the new Brazilian cybersecurity mandates compare to FDA and EU standards? - What are the biggest compliance mistakes companies make when entering this new pathway? - Is local data hosting now a non-negotiable for AI medical devices in Brazil? - How can you leverage your existing technical dossier for this new, faster submission? - What specific documentation is ANVISA demanding to prove cybersecurity robustness? - Are there hidden costs associated with meeting these new stringent requirements? - How can you prepare your Quality Management System for these specific AI regulations? Struggling to navigate these complex regulatory changes in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline your global market access. To learn how we can help you successfully launch in Brazil and beyond, contact us at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking new regulations for AI-powered medical devices just announced by Brazil's ANVISA. This move positions Brazil at the forefront of digital health governance in Latin America, but it also creates a complex new landscape for manufacturers to navigate. We break down what these changes mean, from updated cybersecurity mandates to new requirements for algorithmic transparency. We also explore the immediate impact on MedTech innovators who are looking to enter the lucrative, yet challenging, Brazilian market. Imagine your company has a revolutionary AI diagnostic tool and you were on the verge of entering the Brazilian market. Suddenly, you face a completely new set of rules. Your original submission is now obsolete, your timeline is shattered, and you risk losing your first-mover advantage. How do you adapt your strategy without going back to square one? This week's key takeaways: - What are the three most critical changes in ANVISA's new SaMD framework? - How does the new regulation affect different classes of AI-driven medical devices? - What are the unspoken cybersecurity vulnerabilities that ANVISA is trying to address? - Is Brazil's new stance a barrier to entry or a gateway for serious MedTech companies? - How can you leverage your existing technical documentation for the new submission process? - What are the biggest potential pitfalls in the new clinical data requirements? - Does this regulatory shift signal a larger trend across other LATAM markets? Navigating these shifts requires deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local experts with advanced AI tools to streamline market access. Don't let regulatory hurdles slow your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help you succeed in Brazil and over 30 other markets worldwide.

In this episode, we dissect the immediate impact of Brazil's new ANVISA resolution, RDC 848/2024. This isn't just another regulatory update; it's a fundamental shift in how Brazil evaluates the safety and performance of medical devices, with a sharp new focus on lifecycle risk management and cybersecurity. We explore how this change disrupts the conventional market entry strategy for international MedTech companies. A previously straightforward submission process now requires a new level of evidence, particularly for connected devices and Software as a Medical Device (SaMD), creating unforeseen delays and costs for those unprepared. **Key Questions Answered:** * Why is Brazil's RDC 848/2024 more than just a standard update? * What are the new, unwritten cybersecurity requirements ANVISA now expects for SaMD? * How does this resolution impact your existing FDA or CE-marked technical files? * Is your current risk management plan now obsolete for the Brazilian market? * What specific threat modeling is now necessary for connected devices? * How can you prevent a six-month delay on your product launch in Brazil? * What are the hidden compliance costs associated with this new regulation? Navigating these complex changes requires deep local expertise and a proactive strategy. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Let us help you turn regulatory hurdles into market opportunities. Contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a game-changing regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just launched a new "reliance pathway," promising to dramatically accelerate market access for high-risk medical devices that have already been approved by authorities like the US FDA. This could slash years off of registration timelines. In this episode, we unpack the reality behind the hype. We explore the massive opportunities this creates for international manufacturers and the critical details that could make or break a successful submission. Learn what "essentially identical" really means for your product and why local compliance is more important than ever, even with this new shortcut. **What You'll Learn:** 1. What is ANVISA's new reliance pathway and which foreign approvals are accepted? 2. How much faster can your Class III or IV device get to market under this new rule? 3. What are the most common "hidden hurdles" that could disqualify you from the optimized review? 4. Does your product's indication for use perfectly match your foreign approval? 5. Why is a local Brazil Registration Holder (BRH) still absolutely essential for success? 6. How does this change the strategic importance of Brazil in your global expansion plans? 7. What are the key differences between the reliance dossier and a standard submission? Navigating regulatory shifts like Brazil's new reliance pathway is critical for market success. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI to streamline market access across more than 30 countries. Let us be your local representative in Brazil and ensure your submission is optimized for the fastest possible approval. Contact us at [email protected] or visit https://pureglobal.com/ to secure and accelerate your market presence.

Brazil just rewrote the rules for digital health. Last week, ANVISA published its new regulatory framework for Software as a Medical Device (SaMD), creating an urgent new landscape for MedTech companies. This update introduces a new risk classification system, expedited pathways for some devices, and significant new hurdles for high-risk AI and machine learning technologies. This episode of LATAM MedTech Insights unpacks the critical details of this regulatory shift. We explore the specific requirements that international companies must meet, including the complex pre-approval process for algorithm changes and the stringent new data privacy rules tied to Brazil's LGPD. For companies in the digital health space, understanding these changes is not just important, it's essential for survival and success in Latin America's largest market. **Key Takeaways From This Episode:** * How does Brazil's new four-tier risk classification for SaMD differ from the FDA and MDR frameworks? * What is an 'Algorithm Change Protocol' and why is it now a mandatory submission for AI-driven devices? * Are there new data localization requirements under the updated cybersecurity rules? * Which types of SaMD can now benefit from an expedited registration pathway? * How will ANVISA's new rules impact the use of foreign clinical data in submissions? * What are the immediate compliance risks for devices already on the Brazilian market? * Why is a local representative more critical than ever under this new framework? **Unlock Global Markets with Pure Global** Navigating complex regulatory shifts like Brazil's new SaMD framework is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. From initial strategy and technical dossier submission to post-market surveillance and local representation, we are your partner in over 30 markets worldwide. Don't let regulatory hurdles slow your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your entry into the LATAM market and beyond.

This week, we dissect a major regulatory shift in Brazil's MedTech landscape. ANVISA has just rolled out its new strategic framework for Software as a Medical Device (SaMD) and AI, aiming to align with global standards. But what does this mean for the innovators on the ground?. While harmonization promises safer and more effective digital health tools, the new requirements could inadvertently create significant barriers for local startups. This episode explores how the heightened demands for clinical data and cybersecurity might give large multinational corporations a distinct advantage in one of Latin America's biggest markets. **Case In Point:** Consider a promising Brazilian startup that has developed an AI-powered tool for early cancer detection. They were on the verge of launching, but ANVISA's new rules now demand a level of clinical evidence and cybersecurity documentation that triples their projected costs and delays their market entry by a year. They're now facing a critical pain point: can they secure new funding to meet these demanding standards before a well-funded international competitor with existing global approvals captures the market?. **Key Takeaways:** - How do ANVISA's new SaMD rules fundamentally differ from the previous regulations?. - What specific cybersecurity vulnerabilities must Brazilian MedTech startups now address to be compliant?. - Can leveraging an existing FDA clearance or CE marking truly fast-track the new ANVISA process?. - What are the three biggest mistakes a local company can make when submitting their new SaMD technical dossier?. - Is the cost of compliance under the new framework becoming prohibitive for early-stage innovators?. - How does this regulatory shift impact investment trends in Brazil's burgeoning digital health sector?. - What are the specific changes to the list of Equivalent Foreign Regulatory Authorities and how can you leverage them?. Navigating these turbulent regulatory waters is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in Brazil and over 30 other markets. From initial regulatory strategy and AI-powered technical dossier preparation to acting as your local in-country representative, we streamline your path to market. Don't let regulatory hurdles block your innovation. Contact us at [email protected] or visit https://pureglobal.com/ to learn how our technology and expert team can accelerate your global market access.

In this episode of LATAM MedTech Insights, we dissect the breaking news from Brazil. In the final week of March 2026, ANVISA released a surprise guidance document for Software as a Medical Device (SaMD), creating immediate and significant new hurdles for foreign manufacturers. We explore the specific changes to clinical data requirements and cybersecurity protocols that have caught the industry off guard. This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this means for your product launch timelines and budgets, offering a clear-eyed look at the new landscape. **A Case in Point:** Imagine a promising European MedTech company, weeks from launching its revolutionary AI diagnostic tool in Brazil. Their strategy was solid, based on their successful EU MDR approval. But overnight, ANVISA's new guidance invalidates their clinical data and demands a local cybersecurity infrastructure they don't have. Their launch is frozen, and millions in projected revenue are at risk. This is the exact challenge many companies are now facing. **Key Questions Answered in This Episode:** * What are the most critical changes in ANVISA's new SaMD guidance you must know? * How does the new emphasis on local Brazilian patient data impact your clinical strategy? * Is your current cybersecurity framework compliant with the new mandatory protocols? * Why is a CE mark or FDA clearance no longer a shortcut for entering the Brazilian market? * What are the three most common mistakes foreign companies are making in response to this news? * How can this regulatory hurdle be turned into a competitive advantage? To navigate the complexities of global market access, you need a partner with deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline market entry. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your market access in Brazil and beyond.

This episode of LATAM MedTech Insights dives into the immediate fallout from ANVISA's sudden enforcement of its Unique Device Identification (UDI) system in Brazil. We unpack the operational chaos this is causing for MedTech manufacturers who were unprepared for the complex data submission and labeling requirements. We explore how this regulatory shift is more than a bureaucratic hurdle. it represents a fundamental change in what it takes to access and succeed in Latin America's largest market. We discuss the critical role of the Brazil Registration Holder (BRH) and how a simple data mismatch can derail an entire product launch. A specific case we're seeing is a European scale-up whose fully approved diagnostic device is now blocked from the Brazilian market. Their multi-million dollar launch is on hold, not due to product quality, but because of a failure to meet the new UDI data submission protocols before their shipment arrived, a critical detail that has jeopardized their entire market entry strategy. Key Takeaways This Episode: 1. Why is ANVISA's new UDI enforcement causing a crisis for even experienced MedTech companies? 2. What are the most common mistakes manufacturers make when submitting UDI data to the Brazilian database? 3. How can your choice of a Brazil Registration Holder make or break your market access right now? 4. Is this UDI requirement just a Brazilian issue, or is it the blueprint for the rest of Latin America? 5. What are the hidden costs of UDI non-compliance that go far beyond regulatory fines? 6. How does this new rule impact your existing supply chain and logistics in Brazil? 7. Are your global technical dossiers truly prepared for these new local data integration demands? Navigating complex regulatory landscapes is our expertise. Pure Global offers end-to-end solutions for MedTech companies, combining local, in-country experts with advanced AI tools to streamline global market access. From regulatory strategy and technical dossier submission to serving as your local representative in Brazil, we ensure you are always ahead of the curve. Don't let regulatory surprises disrupt your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the sudden and impactful new regulation from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). International manufacturers are now facing unprecedented requirements for localized clinical data and stringent cybersecurity protocols, effectively rewriting the rulebook for market access in Latin America's largest economy. We explore the immediate consequences of this regulatory shift, moving beyond the headlines to analyze the strategic and financial implications. We discuss why existing clinical data from bodies like the FDA or the EU may no longer be sufficient for ANVISA and what this means for your product launch timeline. This episode provides the critical insights you need to understand and navigate this challenging new environment. **Key Takeaways This Episode:** * How does Brazil's new rule redefine the clinical data requirements for AI-driven SaMD? * What are the specific cybersecurity mandates that international manufacturers are most likely to overlook? * Why might your existing technical dossier be immediately rejected under this new framework? * What is the single biggest mistake companies make when adapting their global strategy for Brazil's new regulations? * Are there new local data residency requirements you haven't considered for your cloud-based platform? * How can you turn this new regulatory hurdle into a competitive advantage? Navigating sudden regulatory shifts is a core challenge for global MedTech companies. At Pure Global, we offer end-to-end regulatory consulting solutions, combining deep local expertise in markets like Brazil with advanced AI and data tools to streamline your market access. From developing a new clinical strategy to ensuring your cybersecurity plan meets ANVISA's strict standards, we act as your local partner to turn regulatory complexity into a clear pathway to success. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help.

In this episode of LATAM MedTech Insights, we dissect the groundbreaking new regulation from Brazil's ANVISA, RDC 922/2026, which just rewrote the rules for AI-powered medical software. This isn't just an update; it's a seismic shift that introduces mandatory local clinical data requirements, impacting market access timelines and costs for foreign manufacturers. We explore the immediate consequences for MedTech innovators, especially those relying on existing FDA or CE Mark approvals. Learn what this increased scrutiny means for your product's classification, the validation process, and your overall launch strategy in Latin America's largest market. **Case In Point:** A promising US-based AI diagnostics company had their Brazilian launch plans shattered overnight by the new RDC 922. Their reliance on FDA clinical data is no longer enough, forcing them into an unexpected, costly, and lengthy local clinical study. Their entire LATAM expansion is now in jeopardy, a stark reminder that global regulatory approvals don't guarantee local market access. **This Episode's Key Questions:** - How does ANVISA's new RDC 922/2026 specifically reclassify AI diagnostic software? - Are my existing FDA or CE Mark clinical studies now invalid for a Brazilian submission? - What are the new mandatory requirements for local clinical data from the Brazilian population? - How will this regulatory shift impact the cost and timeline for market entry into Brazil? - What are the critical mistakes to avoid when adapting your technical dossier for this new framework? - Could this new Brazilian regulation signal a coming trend for other LATAM markets like Mexico or Colombia? - How can you turn this regulatory hurdle into a competitive advantage? Navigating complex, sudden regulatory changes is our specialty. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your path to market.

In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote patient monitoring tools, already established in Brazil, now faces an urgent compliance crisis. Their current registration is invalid, and they must rapidly re-engineer their product's data architecture and conduct a full cybersecurity audit to avoid being forced off the market. This is a costly and complex challenge that could halt their regional revenue stream. Key Takeaways: * What are the specific cybersecurity demands in ANVISA's new instruction for connected devices? * Do your existing products in Brazil now face an immediate compliance gap? * How will the new data localization rules impact your operational costs and IT infrastructure? * What is the new role and liability of local importers in ensuring device cybersecurity? * Are you prepared for a complete technical dossier re-submission for your software-based devices? * Why is Brazil making this sudden move, and which countries in LATAM are likely to follow? * How can this regulatory hurdle be turned into a competitive advantage? Struggling to keep up with unpredictable regulatory changes in LATAM? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline market access. Whether it's navigating Brazil's new cybersecurity rules or expanding into Mexico and Colombia, we act as your local representative to secure and maintain your market presence. Contact us for a strategic consultation at [email protected] or visit https://pureglobal.com/.

Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what it really takes to succeed in this promising market. **A Case Study in Foresight:** An American AI diagnostic firm sees the news from Brazil and fast-tracks its expansion plan. Their device, already FDA-cleared, seems like a perfect fit. But their submission is quickly flagged. The reason? Their cloud data processing is handled on servers in the United States, a direct violation of the unwritten expectation of LGPD compliance for local data handling. Their market entry is now frozen, facing the unexpected and costly decision of whether to build new data infrastructure just for one market. **Key Takeaways:** * What is CFM Resolution 2,454/2026 and why is it more than just an approval pathway? * How does Brazil's LGPD law create a unique regulatory hurdle for AI medical devices? * Why might your global data strategy be incompatible with the Brazilian market? * What are the potential costs associated with data localization for MedTech companies? * How can a "privacy-by-design" approach give you a competitive advantage in Brazil? * What are the key differences between LGPD and GDPR that you must know? * Why is understanding the local regulatory culture just as important as reading the rules? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from developing your regulatory strategy to acting as your local representative in Brazil and over 30 other markets. Our combination of local expertise and advanced AI tools streamlines your path to market access. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, technical documentation, and your overall market access strategy in Brazil. **Case Study:** A European MedTech firm has a powerful AI diagnostic software for radiology. They considered Brazil a prime market but were operating in a grey area. Now, the CFM resolution provides a path, but one with new obstacles. How must they adapt their AI's user interface to meet the "human oversight" mandate, and how can they prove their data processing is fully compliant with Brazil's stringent LGPD privacy law without a costly redesign? **Key Takeaways:** - How does the CFM's focus on physician liability change your product's risk management file? - Is your AI's algorithm explainable enough to meet the new transparency requirements? - What specific steps must you take to ensure your data practices are compliant with both the CFM resolution and Brazil's LGPD? - How will you need to modify your training and support materials for Brazilian medical professionals? - Does this new resolution require a separate clinical validation study for the Brazilian population? - How could this physician-centric framework in Brazil influence future AI regulations in other LATAM countries? At Pure Global, we offer end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies. We combine local expertise with advanced AI and data tools to streamline your global market access, including navigating complex new frameworks like Brazil's AI regulations. To get your product to market efficiently and correctly, contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price? Key Takeaways: - What exactly is ANVISA's new "Agiliza-IA" program? - Why are the new local clinical data requirements a game-changer for foreign companies? - What are the specific cybersecurity protocols you must now meet for approval? - How did a local startup beat global giants to the first approval? - Is Brazil's 90-day promise a real opportunity or a hidden trap? - What does this mean for the future of MedTech regulation across LATAM? - How can you start preparing your technical dossier for this new pathway today? At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just unveiled a new "Reliance" pathway, promising an incredible 80% reduction in review time for medical devices already approved by MDSAP authorities. This could dramatically accelerate market access for many international firms. However, this new shortcut comes with a critical catch. At the same time, ANVISA has implemented stricter, IMDRF-aligned standards for essential safety and performance requirements. This means the technical documentation bar has been raised significantly, potentially creating new hurdles even for experienced manufacturers. We break down the opportunity and the hidden challenge. We explore the case of a U.S. orthopedic implant company, whose dream of a fast-track approval was met with the harsh reality of a complete technical file overhaul, forcing them to navigate the gap between their existing FDA compliance and Brazil's new, tougher standards. This week, you'll learn: - What are the exact eligibility criteria for ANVISA's new Reliance pathway? - How does the new RDC 848 resolution change your technical documentation checklist forever? - Which common gaps exist between an FDA-approved file and the new IMDRF-based requirements? - Is the Reliance pathway a guaranteed approval, or are there still hidden pitfalls? - What is the first step your company should take right now to adapt to this new landscape? - How can you leverage your existing international approvals most effectively for the Brazilian market? - What are the critical risk management updates required under the new regulations? Navigating the complexities of global markets is our expertise. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced data tools to streamline your market access. Whether it's adapting your technical dossier for Brazil's new standards or acting as your local representative, we clear the path for your innovation. Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at [email protected] or visit https://pureglobal.com/ to secure your market presence.

Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are eligible for the new COFEPRIS-FDA fast-track program? * What exact FDA documentation is now required for a streamlined submission to COFEPRIS? * How does this reliance pathway change the responsibilities of your Mexican Registration Holder? * What are the new, immediate post-market reporting obligations under this program? * Is this accelerated pathway a sign of a permanent shift in Mexican regulatory policy? * How can you leverage your existing 510(k) or PMA to maximize this opportunity? * What are the hidden compliance risks that could disqualify you from the program? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Mexico. Whether you need to prepare a dossier for this new pathway or develop a broader LATAM strategy, our team is here to help. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a US-based company with FDA clearance found its market entry plan blocked overnight, needing a complete overhaul of its technical dossier to meet Brazil's new, specific cybersecurity and clinical data requirements, delaying their launch by eight months. Key Takeaways: - How does ANVISA's RDC 848/2024 impact your current Brazil registration strategy? - Are your device's cybersecurity protocols robust enough for the new, explicit requirements? - What are the biggest compliance gaps this regulation creates for devices already approved in the EU or US? - Why is a 'total lifecycle' approach to risk management now mandatory for market access in Brazil? - How can you proactively update your technical dossier to prevent rejection under these new rules? - What specific clinical evidence is now required to prove performance claims to ANVISA? - Does this new regulation affect your post-market surveillance obligations? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies to streamline global market access. We combine local expertise in over 30 markets, including Brazil, with advanced AI to navigate complex changes like RDC 848/2024, ensuring your path to market is efficient and successful. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dive into a major regulatory shift in Brazil. ANVISA has just launched an exciting fast-track approval process for AI-powered medical software, creating a huge opportunity for MedTech innovators to enter Latin America's biggest market faster than ever before. But this new speed comes with a hidden challenge. The new pathway is tied to incredibly strict data privacy and cybersecurity rules based on Brazil's LGPD. These new requirements around data storage and patient consent are already creating significant hurdles, turning a golden opportunity into a complex compliance trap for unprepared companies. We explore a real-world case of a US MedTech company whose Brazilian launch was stopped in its tracks by these new data privacy rules, forcing them into a difficult and expensive decision. Their cutting-edge diagnostic tool is ready, but their data is not. Key Takeaways This Episode: 1. What are the specific criteria for ANVISA's new AI software fast-track pathway? 2. How do Brazil's new data privacy mandates specifically impact MedTech device submissions? 3. Will your existing international clinical data be considered valid under the new patient consent rules? 4. What are the real costs and penalties for non-compliance with Brazil's data localization requirements? 5. Does the new regulation give local Brazilian MedTech companies an unfair advantage? 6. How can you redesign your regulatory strategy to seize the fast-track opportunity while avoiding the privacy trap? 7. What specific cybersecurity vulnerabilities is ANVISA now targeting in its assessments? Struggling to keep up with the dynamic regulatory landscape in Latin America? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local, on-the-ground expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don’t let complex regulations be a barrier to entry. Contact us at [email protected] or visit us at https://pureglobal.com/ to learn how we can accelerate your path to market.

In this episode, we dissect a sudden, unannounced regulatory shift from Brazil's ANVISA that is impacting the global Software as a Medical Device (SaMD) industry. Last week, the agency mandated a new, complex cybersecurity audit for all SaMD products, to be conducted exclusively by a short list of local Brazilian firms. This surprise move creates a significant new hurdle for market access. We explore the immediate consequences of this decision, discussing the operational and financial strains it places on international MedTech companies aiming to enter or expand within Latin America's largest market. Imagine your product launch, years in the making, being halted indefinitely by a bureaucratic requirement you had no way to anticipate. This is the critical pain point for SaMD manufacturers today, forcing them to scramble for local expertise and navigate a vague, complex, and costly new compliance layer. What you'll learn in this episode: - What are the specific, technical demands of ANVISA's new cybersecurity audit? - Why was this critical requirement left off the official public regulatory agenda? - How can you vet and manage the newly-approved local audit firms from abroad? - What does this move signal about Brazil's strategy for digital health sovereignty? - Are other LATAM countries like Mexico or Colombia likely to follow Brazil's lead? - How can you update your regulatory strategy to protect against these types of surprise hurdles? - What are the immediate steps to take if your SaMD submission is currently in progress? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts and advanced AI-driven data tools, we provide end-to-end regulatory consulting to streamline your market access. For help navigating the complexities of the Brazilian market, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dissect the groundbreaking new regulation from Brazil's ANVISA. A new fast-track approval pathway for AI and Machine Learning medical software promises to slash market entry timelines, opening the door for innovative diagnostic technologies to reach one of LATAM's biggest markets. However, a critical and complex clause lurks within the fine print: a strict data residency requirement. We explore how this 'data trap' creates significant operational and financial hurdles for foreign MedTech companies, potentially offsetting the benefits of the accelerated review process and reshaping market entry strategies for the entire region. Imagine you're a startup with a revolutionary AI diagnostic tool. You see ANVISA's announcement and plan your Brazilian launch, only to discover you must now build or lease an entire local data infrastructure, navigating both healthcare and data privacy laws. We look at the real-world costs and strategic pivots this requires. Key questions from this episode: - What specific types of AI medical software are eligible for ANVISA's new fast-track? - How does the data residency requirement change the cost-benefit analysis for entering Brazil? - What are the key differences between Brazil's LGPD and GDPR that companies must consider? - Are there compliant local cloud providers in Brazil ready for this MedTech influx? - Could this regulation set a new data sovereignty precedent for other LATAM markets? - What are the immediate steps a company should take if they were targeting Brazil with their AI software? - How does this impact the valuation and investment appeal of foreign AI MedTech startups? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for manufacturers aiming to enter or remain in Latin America's largest market. We uncover the specific documentation now required and explain why your existing FDA or CE marking might not be enough. This episode delves into the real-world impact of these changes. Imagine your state-of-the-art health app, already successful in the U.S. and Europe, is suddenly halted at the Brazilian border. Your dossier is rejected for failing to meet new, highly specific cybersecurity criteria. This is the new reality for many, causing costly delays and demanding a complete overhaul of regulatory strategy. Key questions answered in this episode: - What are the three critical documents ANVISA now demands for SaMD cybersecurity? - How can you leverage your existing international documentation for the new Brazilian requirements? - Is on-the-ground cybersecurity testing now mandatory in Brazil? - What are the most common pitfalls leading to dossier rejection under the new framework? - How can proactive post-market surveillance protect you from a product recall? - Does the new rule apply to legacy devices already on the market? - How will this impact the timeline and cost of entering the Brazilian market? Struggling with global market access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI to streamline market entry. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This episode of LATAM MedTech Insights dives deep into the lingering challenges of Brazil's landmark medical device regulation, ANVISA RDC 751. Years after its implementation, we explore the real-world operational hurdles that international MedTech companies continue to face, moving beyond the basics to uncover the hidden complexities in risk classification, technical documentation, and post-market surveillance. We analyze the costly surprises that arise from device reclassification. For instance, a manufacturer of orthopedic implants saw their product up-classified from Class II to Class III, triggering unexpected requirements for extensive, local clinical data. This single issue delayed their market entry by over a year and added hundreds of thousands of dollars in unplanned expenses, a critical pain point for any company looking to expand into Latin America's largest market. Key Questions Answered in this Episode: - Is your device's risk class under RDC 751 secretly jeopardizing your launch timeline? - How can you manage the intensive new Technical Dossier requirements without draining resources? - What are the most common post-market surveillance mistakes companies are making in Brazil? - Why is your choice of a Brazil Registration Holder (BRH) more critical than ever? - Are you prepared for ANVISA's increased scrutiny on clinical data for medium-risk devices? - How does Brazil's harmonization with global standards create both opportunities and traps? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, ensuring you navigate complex markets like Brazil with confidence. For a strategic partner in your global expansion, contact us at [email protected] or visit https://pureglobal.com/.

Brazil's MedTech market is undergoing a seismic regulatory shift. ANVISA, the national health surveillance agency, is rolling out a series of major updates, including the new RDC 848/2024, which redefines essential safety and performance requirements with a strong focus on lifecycle risk management and cybersecurity. This is creating a new, complex web of compliance for manufacturers. This episode of LATAM MedTech Insights unpacks the practical implications of these changes. We go beyond the headlines to explore the operational hurdles, such as the mandatory transition to a new digital certificate platform by 2025. We reveal the hidden pitfalls that are already causing submission delays and rejections for unprepared foreign companies trying to enter or stay in Latin America's largest market. We explore the real-world scenario of a mid-sized European device maker whose Brazilian market entry was stalled for six months. They successfully passed clinical trials, but their entire submission was rejected due to a documentation technicality in ANVISA’s new, confusing certificate issuance system. This episode breaks down how to avoid that costly mistake. Key Takeaways: 1. How does ANVISA's new RDC 848/2024 fundamentally change safety requirements for your device? 2. Is your current technical dossier prepared for the upcoming cybersecurity mandates? 3. What are the biggest pitfalls when transitioning from the old 'Sicert' to the new submission platform? 4. Why might your existing risk classification under RDC 751 need urgent re-evaluation? 5. How will these new rules impact your timeline and budget for entering the Brazilian market? 6. Are you treating Brazilian compliance as a lifecycle activity or a one-time submission? 7. What specific documentation changes are required for the new 2025 certificate tool? Don't let regulatory hurdles block your access to the vibrant Brazilian market. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline global market access. We act as your local representative, manage technical dossiers, and ensure continuous compliance in over 30 markets. To build a resilient regulatory strategy for Brazil and beyond, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a sudden and critical regulatory update from Brazil's ANVISA that is sending ripples through the AI medical device community. A new technical clarification has redefined the rules for software-based devices, creating unexpected and costly new hurdles for foreign manufacturers trying to enter Latin America's biggest market. We explore the two main challenges this clarification presents: a new, strict requirement for clinical data from the Brazilian population, and complex cybersecurity documentation mandates that must be localized in Portuguese and aligned with local data laws. This episode breaks down what these changes mean on the ground and why your existing global regulatory dossier may no longer be enough for Brazil. A German MedTech scaleup, with a cutting-edge AI diagnostic software already CE-marked, targeted Brazil for its next major expansion. They prepared their submission based on the existing RDC 751 regulation, using their robust European clinical trial data. Their submission was just put on hold by ANVISA last week. The reason? The new technical note requires clinical validation on the Brazilian population, data they do not have. Now, they face an unexpected delay of at least 12-18 months to conduct a local study, a costly setback that puts their entire LATAM strategy at risk. Key questions from this episode: - Is your existing clinical data package now obsolete for your ANVISA submission? - What are the specific requirements for validating an AI algorithm on the Brazilian population? - Does your cybersecurity risk assessment comply with Brazil's LGPD data law? - Are you prepared to submit highly technical documents in flawless, localized Portuguese? - How can you conduct a supplementary local clinical study without a physical presence in Brazil? - What are the hidden costs associated with this new ANVISA clarification? - Could a local regulatory partner help you bypass the need for a full new clinical trial? Don't let regulatory surprises derail your entry into Latin America's largest market. Pure Global combines deep local expertise with advanced AI tools to navigate complex requirements like Brazil's new SaMD regulations. We provide end-to-end support, from regulatory strategy and local representation to compiling the technical dossier needed to succeed. Let us be your partner in streamlining global market access. Contact us at [email protected] or visit us at https://pureglobal.com/.